SCHEMBL13484112

SCHEMBL13484112

COc1ccc2cc(CC(C)C)ccc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.54
AKR1C3 P42330 1/20 0.54
AKR1C2 P52895 1/20 0.54
CYP1A2 P05177 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAPT P10636 1/20 0.51
MAOA P21397 1/20 0.51
SLC6A2 P23975 1/20 0.51
RAB9A P51151 1/20 0.51
SLC6A3 Q01959 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PTGS2 P35354 1/20 0.51
RAD52 P43351 1/20 0.51
PAX8 Q06710 1/20 0.51
CYP2A6 P11509 1/20 0.50
ABCB11 O95342 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28292686 0.85 HTR2A (0.57) PTGS1AKR1C3CYP1A2LMNAPTGS2
SCHEMBL9546445 0.85 PTGS1 (0.56) PTGS1AKR1C3AKR1C2CYP1A2KDM4E
SCHEMBL29818641 0.85 SLC6A4 (0.70) TAAR1SLC6A4
SCHEMBL30824303 0.85 PTGS1 (0.56) PTGS1AKR1C3AKR1C2CYP1A2KDM4E
SCHEMBL9546449 0.85 PTGS1 (0.56) PTGS1AKR1C3AKR1C2CYP1A2KDM4E
SCHEMBL13484409 0.85 SLC6A4 (0.70) TAAR1SLC6A4
SCHEMBL30776613 0.85 PTGS1 (0.56) PTGS1AKR1C3AKR1C2CYP1A2KDM4E
Hydrochloric Acid SCHEMBL11281141 0.84 SLC6A4 (0.68) TAAR1SLC6A4
SCHEMBL21055097 0.83 ALOX15 (0.50) CYP1A2
SCHEMBL11015452 0.82 PTGS1 (0.53) PTGS1AKR1C3AKR1C2CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190497-A1 FLUORESCENT SUBSTRATES FOR MONOAMINE TRANSPORTERS AS OPTICAL FALSE NEUROTRANSMITTERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-07-25 US disclosed
US-8337941-B2 Fluorescent substrates for monoamine transporters as optical false neurotransmitters THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-12-25 US disclosed
US-20100035279-A1 Fluorescent Substrates for Monoamine Transporters as Optical False Neurotransmitters NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-02-11 US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-20090170934-A1 MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC NICOX SA 2009-07-02 US disclosed
US-20090096314-A1 ELECTRIC MOTOR HONDA MOTOR CO., LTD. (JP) 2009-04-16 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035279-A1 Fluorescent Substrates for Monoamine Transporters as Optical False Neurotransmitters SLC18A2, SLC6A2, SLC18A3 PTGS1 2653/4885AKR1C3 1010/4885AKR1C2 1341/4885
US-20130190497-A1 FLUORESCENT SUBSTRATES FOR MONOAMINE TRANSPORTERS AS OPTICAL FALSE NEUROTRANSMITTERS SLC18A2, SLC6A2, SLC18A3 PTGS1 2653/4885AKR1C3 1010/4885AKR1C2 1341/4885
US-20090170934-A1 MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC NOS2, NOS1, NOS3 PTGS1 28/4885AKR1C3 39/4885AKR1C2 65/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA PTGS1 3434/4885AKR1C3 524/4885AKR1C2 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.